neovascular glaucoma
Conditions
Interventions
Experimental group:Trabeculectomy combined with anterior chamber proliferative membrane interception
Sponsors
Affiliated Eye Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Sign the informed consent form and be willing to follow up according to the time specified in the trial; 2. Aged 18 to 75 years, gender is not limited; 3. Patients with neovascular glaucoma diagnosed with neovascularization on the surface of the iris and (or) the angle of the chamber; 4. The intraocular pressure is still greater than 22mmHg (1mmHg=0.133kPa) under the maximum intraocular pressure lowering drug.
Exclusion criteria
Exclusion criteria: 1. Neovascular glaucoma secondary to intraocular tumor or inflammation; 2. Severe cardiovascular and cerebrovascular diseases or recent active eye inflammation; 3. History of eye surgery such as cyclocondensation, scleral cerclage, glaucoma trabeculectomy, aqueous drainage valve implantation, and intravitreal silicone oil filling; 4. Patients who are planning to become pregnant, pregnant or breastfeeding; 5. Patients who have uncontrolled systemic diseases or other reasons and are judged by the investigator to be unsuitable to enter this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure;Best-corrected vision acuity;Corneal endothelial cell count; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual field; | — |
Countries
China
Contacts
Public ContactLiang Yuanbo
Affiliated Eye Hospital of Wenzhou Medical University
Outcome results
None listed